MX2020005564A - Sales de 4-amino-n-(1-((3-cloro-2-fluorofnil)amino)-6-metilisoquin olin-5-il)tieno[3,2-d]pirimidino-7-carboxamida, y formas cristalinas de las mismas. - Google Patents

Sales de 4-amino-n-(1-((3-cloro-2-fluorofnil)amino)-6-metilisoquin olin-5-il)tieno[3,2-d]pirimidino-7-carboxamida, y formas cristalinas de las mismas.

Info

Publication number
MX2020005564A
MX2020005564A MX2020005564A MX2020005564A MX2020005564A MX 2020005564 A MX2020005564 A MX 2020005564A MX 2020005564 A MX2020005564 A MX 2020005564A MX 2020005564 A MX2020005564 A MX 2020005564A MX 2020005564 A MX2020005564 A MX 2020005564A
Authority
MX
Mexico
Prior art keywords
amino
thieno
carboxamide
fluorophenyl
pyrimidine
Prior art date
Application number
MX2020005564A
Other languages
English (en)
Inventor
Young Gil Ahn
Kwee Hyun Suh
Chang Hee Park
Seung Hyun Jung
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MX2020005564A publication Critical patent/MX2020005564A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La presente invención se relaciona con una forma cristalina de una sal de 4-amino-N-(1-((3-cloro-2-fluorofenil)amino)-6-metilisoq uinolin-5-il)tieno[3,2-d]-pirimidino-7-carboxamida y una composición farmacéutica que contiene la misma. La forma cristalina de la sal del compuesto puede usarse fácilmente para preparar una composición farmacéutica que contiene la misma como un ingrediente activo.
MX2020005564A 2017-11-30 2018-11-29 Sales de 4-amino-n-(1-((3-cloro-2-fluorofnil)amino)-6-metilisoquin olin-5-il)tieno[3,2-d]pirimidino-7-carboxamida, y formas cristalinas de las mismas. MX2020005564A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762592676P 2017-11-30 2017-11-30
PCT/KR2018/014968 WO2019107971A1 (en) 2017-11-30 2018-11-29 Salts of 4-amino-n-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide, and crystalline forms thereof

Publications (1)

Publication Number Publication Date
MX2020005564A true MX2020005564A (es) 2020-11-06

Family

ID=66665221

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005564A MX2020005564A (es) 2017-11-30 2018-11-29 Sales de 4-amino-n-(1-((3-cloro-2-fluorofnil)amino)-6-metilisoquin olin-5-il)tieno[3,2-d]pirimidino-7-carboxamida, y formas cristalinas de las mismas.

Country Status (12)

Country Link
US (1) US11649246B2 (es)
EP (2) EP3717489B1 (es)
JP (2) JP7235748B2 (es)
KR (1) KR20200084049A (es)
CN (1) CN111655698A (es)
AU (2) AU2018374682B2 (es)
BR (1) BR112020010903A2 (es)
CA (1) CA3084073C (es)
IL (1) IL274969A (es)
MX (1) MX2020005564A (es)
TW (1) TWI805653B (es)
WO (1) WO2019107971A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024509269A (ja) * 2021-03-09 2024-02-29 ジェネンテック， インコーポレイテッド 脳がんの治療における使用のためのベルバラフェニブ
CN117580840A (zh) * 2021-06-30 2024-02-20 基因泰克公司 4-氨基-n-(1-((3-氯-2-氟苯基)氨基)-6-甲基异喹啉-5-基)噻吩并[3,2-d]嘧啶-7-甲酰胺的双甲磺酸盐及其中间体的合成
CN113999206B (zh) * 2021-12-31 2022-04-12 北京鑫开元医药科技有限公司 异喹啉-1,3-二胺类似物、制备方法、药物组合物及其应用
CN114533733A (zh) * 2021-12-31 2022-05-27 北京鑫开元医药科技有限公司 一种异喹啉-1,3-二胺类似物药物制剂及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
ATE191853T1 (de) 1992-07-27 2000-05-15 Us Health Zielgerichte liposome zur blut-hirne schranke
KR20080015888A (ko) 2000-06-28 2008-02-20 테바 파마슈티컬 인더스트리즈 리미티드 카르베딜올
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
US20020065259A1 (en) 2000-08-30 2002-05-30 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
WO2003009815A2 (en) 2001-07-25 2003-02-06 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
CA2507762C (en) 2002-12-03 2013-02-05 Blanchette Rockefeller Neurosciences Institute Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
WO2005025511A2 (en) 2003-09-10 2005-03-24 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
KR101147550B1 (ko) 2009-10-22 2012-05-17 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노［3,2-ｄ］피리미딘 화합물
KR101094446B1 (ko) 2009-11-19 2011-12-15 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,4,7-치환된 티에노［3,2-ｄ］피리미딘 화합물
CA2786438C (en) 2010-01-29 2015-10-13 Hanmi Science Co., Ltd. Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases
SG11201402765TA (en) * 2011-12-30 2014-06-27 Hanmi Pharm Ind Co Ltd THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
EP3551612A4 (en) * 2016-12-07 2020-08-12 MSN Laboratories Private Limited, R&D Center PROCESS FOR THE PREPARATION OF N- (4- (6,7-DIMETHOXYQUINOLIN-4-YLOXY) PHENYL) -N '- (4-FLUOROPHENYL) CYCLOPROPANE-1, 1-DICARBOXAMIDE, (2S) -HYDROXYBUTANYEDIOOR AND ITS POLYDROXYBUTANYMATE

Also Published As

Publication number Publication date
CA3084073C (en) 2023-04-25
CN111655698A (zh) 2020-09-11
BR112020010903A2 (pt) 2020-11-17
EP4295916A2 (en) 2023-12-27
EP3717489A4 (en) 2021-03-31
CA3084073A1 (en) 2019-06-06
US11649246B2 (en) 2023-05-16
AU2022201797A1 (en) 2022-04-07
TWI805653B (zh) 2023-06-21
AU2018374682B2 (en) 2021-12-16
EP3717489A1 (en) 2020-10-07
US20200308187A1 (en) 2020-10-01
EP4295916A3 (en) 2024-03-20
EP3717489B1 (en) 2023-12-27
JP7235748B2 (ja) 2023-03-08
KR20200084049A (ko) 2020-07-09
JP2021504437A (ja) 2021-02-15
WO2019107971A1 (en) 2019-06-06
AU2018374682A1 (en) 2020-06-25
IL274969A (en) 2020-07-30
TW201925207A (zh) 2019-07-01
JP2022191306A (ja) 2022-12-27
EP3717489C0 (en) 2023-12-27

Similar Documents

Publication Publication Date Title
MX2020005564A (es) Sales de 4-amino-n-(1-((3-cloro-2-fluorofnil)amino)-6-metilisoquin olin-5-il)tieno[3,2-d]pirimidino-7-carboxamida, y formas cristalinas de las mismas.
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
PH12018500975A1 (en) 7-(thiazol-5-yl) pyrrolopyrimidine compound as tlr7 agonist
PH12018501644A1 (en) Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
TN2018000395A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2017000521A1 (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MX348228B (es) Cristal de derivados de 6,7-insaturado-7-carbamoil morfinano y metodo para producir el mismo.
NZ714558A (en) Formulation comprising a hypolipidemic agent
WO2015114395A9 (en) Process for the preparation of vortioxetine salts
MX2021004000A (es) Derivados de piperidina.
MX2019012454A (es) Compuesto solido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol.
PH12019502562A1 (en) N-substituted indole derivatives
SG11201901962QA (en) Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof
PH12015502632A1 (en) Cxcr7 receptor modulators
MX367772B (es) Derivados de n-(2,3-dihidro-1h-pirrolo[2,3,b]piridin-5-il)-4-quina zolinamina y n-(2,3-dihidro-1h-indol-5-il)-4-quinazolinamina novedosos como inhibidores de perk.
PH12020550703A1 (en) Sulfonamide compounds and use thereof
MX2016001422A (es) Composicion farmaceutica de fingolimod.
MY194711A (en) Novel annelated phenoxyacetamides
PH12018501331A1 (en) Crystalline forms of thienopyrimidine compound
PH12021550439A1 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
MX2019015478A (es) Una nanosuspension farmaceutica para el tratamiento de infeccion por vih.
PH12020551736A1 (en) The crystalline forms of a compound
PH12018501314A1 (en) Crystalline forms of hydrochloride salts of thienopyrimidine compound
NZ630795A (en) Crystalline form of vsn16